Eiger BioPharmaceuticals, Inc.
EIGRQ · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $10 | $14 | $31 | $40 |
| - Cash | $25 | $28 | $23 | $15 |
| + Debt | $41 | $41 | $41 | $40 |
| Enterprise Value | $26 | $27 | $49 | $65 |
| Revenue | $4 | $3 | $5 | $4 |
| % Growth | 18.5% | -30.9% | 12.7% | – |
| Gross Profit | $4 | $3 | $5 | $4 |
| % Margin | 92.6% | 90.2% | 102.7% | 92.5% |
| EBITDA | -$12 | -$16 | -$19 | -$21 |
| % Margin | -311.5% | -511.7% | -412.8% | -517.4% |
| Net Income | -$13 | -$18 | -$21 | -$23 |
| % Margin | -353.8% | -561.9% | -445.7% | -553.3% |
| EPS Diluted | -9.09 | -12.2 | -14.02 | -15.48 |
| % Growth | 25.5% | 13% | 9.4% | – |
| Operating Cash Flow | -$14 | -$15 | -$22 | -$24 |
| Capital Expenditures | -$0 | $0 | -$0 | -$0 |
| Free Cash Flow | -$14 | -$15 | -$22 | -$24 |